November 3rd, 2012
ALTITUDE Autopsy Shows What Went Wrong With Aliskiren
Larry Husten, PHD
In its short lifespan the direct renin inhibitor aliskiren (a.k.a., Rasilez or Tekturna) rapidly declined from being a highly promising, first-of-its kind drug to a major failure. The death blow was struck last December with the early termination of the ALTITUDE trial, after the data and safety monitoring committee found an increased risk in patients taking aliskiren. Now the final results […]
August 26th, 2012
First Detailed Look At Why Aliskiren Failed To Gain ALTITUDE
Larry Husten, PHD
This once-promising renin inhibitor was no better than placebo when it came to the composite outcome, but showed worrisome trends, especially when it came to stroke.
NEJM Journal Watch — Recent Cardiology Articles- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy
- Does Colchicine Reduce Cardiac Events After Myocardial Infarction?
- First-Line Therapy for Ventricular Tachycardia After MI: What's the Best Approach?